Literature DB >> 3208201

Activity of phosphoenolpyruvate carboxylase of an anthracycline-producing streptomycete.

M L Dekleva1, W R Strohl.   

Abstract

During fermantation studies on the production of anthracycline antibiotics by Streptomyces C5, it was observed that among the intermediate metabolism enzymes tested, only phosphoenolpyruvate carboxylase (PEPCase; EC 4.1.1.31) increased significantly in specific activity during stationary phase. The specific activity of the Streptomyces C5 PEPCase increased ca. 3-fold during antibiotic production phase from the logarithmic phase levels. To characterize the regulation of the enzyme further, the Streptomyces C5 PEPCase was purified 150-fold from crude extracts. Acetyl-CoA and Mg2+ were shown to be required for PEPCase activity. The activity of the partially purified PEPCase was stimulated slightly by fructose 1,6-bisphosphate and AMP, and was inhibited severely by oxaloacetate, aspartate, malate, succinate, ATP, citrate, and CoASH.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3208201     DOI: 10.1139/m88-218

Source DB:  PubMed          Journal:  Can J Microbiol        ISSN: 0008-4166            Impact factor:   2.419


  3 in total

1.  Metabolic network analysis of Streptomyces tenebrarius, a Streptomyces species with an active entner-doudoroff pathway.

Authors:  Irina Borodina; Charlotte Schöller; Anna Eliasson; Jens Nielsen
Journal:  Appl Environ Microbiol       Date:  2005-05       Impact factor: 4.792

2.  Phosphoenolpyruvate carboxylase from Streptomyces coelicolor A3(2): purification of the enzyme, cloning of the ppc gene and over-expression of the protein in a streptomycete.

Authors:  H Bramwell; H G Nimmo; I S Hunter; J R Coggins
Journal:  Biochem J       Date:  1993-07-01       Impact factor: 3.857

3.  Carbon-flux distribution within Streptomyces coelicolor metabolism: a comparison between the actinorhodin-producing strain M145 and its non-producing derivative M1146.

Authors:  Fabien Coze; Françoise Gilard; Guillaume Tcherkez; Marie-Joëlle Virolle; Armel Guyonvarch
Journal:  PLoS One       Date:  2013-12-23       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.